Coagulation and Fibrinolysis in Amyloid and Non-amyloid Hemodialysis Patients: Assessment of Local Hemostatic Kinetics Within Arteriovenous Fistulas

Abstract

This study was designed to determine whether systemic amyloidosis is an additional risk factor for he mostatic abnormalities in hemodialysis patients and to evaluate local alterations of the hemostatic process within the patent-functional native arteriovenous fistula (AVF). Concentrations of in vivo molecular hemostatic markers, including prothrombin fragment_{1 +2} (PF 1.2), thrombin antithrombin III complex (TAT) and plasmin-α₂ antiplasmin complex (PAP) were determined in plasma samples taken simultaneously from AVFs and contralat eral upper extremity large veins of hemodialysis patients associated with and without systemic amyloidosis. Seven amyloid (2 women, 5 men, aged 34 ± 6 years), and 13 non-amyloid patients (4 women, 9 men, aged 36 ± 7 years) on maintenance hemodialysis and 20 healthy vol unteers (8 women, 12 men, aged 36 ± 9 years) were in cluded in the study. Peripheral vein PF 1.2 and TAT lev els showed no difference between amyloid and non- amyloid patient groups, but both were significantly higher than control group. PF 1.2 and TAT levels were also found to be elevated in fistulas when compared with that of peripheral vein in both amyloid and non-amyloid pa tient groups. Determination of PAP in peripheral veins of each group revealed significantly higher levels in amyloid hemodialysis patients than in non-amyloid patients and controls. PAP levels were significantly higher in fistulas of amyloid patients than in non-amyloid patients. In con clusion, this study confirms enhanced coagulation and fibrinolysis in hemodialysis patients and excessive fibri nolysis in amyloid patients with remarkable contribu tion of AVF on enhanced coagulation and fibrinolysis.

Keywords

Arteriovenous fistula Fibrinolysis Amyloidosis Plasmin-α2 antiplasmin complex Thrombin-antithrombin III complex Prothrombin frag ment 1+2.

Get full access to this article

View all access options for this article.

References

Lindner A. , Charra B. , Sherrard DJ , Scribner BH Accelerated atherosclerosis in prolonged maintenance hemodialysis . N Engl J Med 1974;290:697.

Ansari A. , Kaupke CJ , Vaziri ND , Miller R. , Barbari A. Cardiac pathology in patients with end-stage renal disease maintained on hemodialysis . Int J Artif Organs 1993;16:31.

Rabelink TJ , Zwaginga JJ , Koomans HA , Sixma JJ Thrombosis and hemostasis in renal disease. Kidney Int 1994;46: 287.

Aoki N. Haemostasis associated with abnormalities of fibrinolysis. Blood Rev 1989;3:11.

Chang JC , Kane KK Pathologic hyperfibrinolysis associated with amyloidosis. Am J Clin Pathol 1984;81:382.

Chazan JA , London MR , Pono LM Long-term survival of vascular accesses in a large chronic hemodialysis population . Nephron 1995;69:228.

Chazan JA , London MR , Pono LM The impact of diagnosis-related groups on the cost of hospitalization for end-stage renal disease patients at Rhode Island Hospital from 1987 to 1990 . Am J Kidney Dis 1992;6:523.

Pearson JD Vessel wall interactions regulating thrombosis. Br Med Bull 1994;50:776.

Remuzzi G. , Perico N. , Zoja C. , Coma D. , Macconi D. , Vigano D. Role of endothelium derived nitric oxide in the bleeding tendency of uremia . J Clin Invest 1990;86:1768.

10.

Swedburg S. , Brown B. , Sigley R. , Wright T. , Gordon D. , Nichols S. Intimal fibromuscular hyperplasia at the venous anastomoses of PTFE grafts in hemodialysis. Circulation 1989;80:1726.

11.

Bush H. , Jakubowski J. , Curl G. , Deykin D. , Nasbeth D. The natural history of endothelial structure and function in arterialized vein grafts. J Vasc Surg 1986;3:204.

12.

Fareed J. , Bick RL , Hoppensteadt DA , Bermes EW Molecular markers of hemostatic activation: applications in the diagnosis of thrombosis and vascular and thrombotic disorders. Clin Appl Thromb Hemost 1995;1:87.

13.

Sagripanti A. , Cupisti A. , Baicchi U. , Ferdeghini M. , Morelli E. , Barsotti G. Plasma parameters of the prothrombotic state in chronic uremia. Nephron 1993;63:273.

14.

Kolb G. , Fischer W. , Seitz R. , et al. Hemodialysis and blood coagulation: the effect of hemodialysis on coagulation factor XIII and thrombin-antithrombin III complex. Nephron 1991; 58:106.

15.

Sultan Y. , London GM , Goldfarb B. , Toulon P. , Marchais SJ

Activation of platelets, coagulation and fibrinolysis in patients on long-term hemodialysis: influence of cuprophan and polacrylonitrile membranes. Nephron

Dial Transplant 1990;5:362.

16.

Brommer Ejp , Schicht I. , Wijngaards G. , Verheijen JH , Rijken DC Fibrinolytic activators and inhibitors in terminal renal insufficiency and in anephric patients. Thromb Haemost 1984;52:311.

17.

Kyle RA , Gertz MA Primary systemic amyloidosis: clinical and laboratory features in 474 cases . Semin Thromb Hemost 1995;32:45.

18.

Hursting MJ , Stead AG , Crout FV , Horvath BZ , Moore BM Effects of age, race, sex, and smoking on prothrombin fragment 1.2 in a healthy population . Clin Chem 1993;39:683.

19.

Deguchi K. , Noguchi M. , Yuwasaki E. , et al. Dynamic fluctuations in blood of thrombin/antithrombin III complex (TAT). Am J Hematol 1991 ;38:86.

20.

Fareed J. , Walenga JM , Bick RL Low molecular weight markers of hemostatic defects: impact of automation on the quantitation of hemostatic disorders. Semin Thromb Hemost 1983;9:354.

21.

Nakamura Y. , Chida Y. , Tomura S. Enhanced coagulation-fibrinolysis in patients on regular hemodialysis treatment. Nephron 1991;58:201.

22.

Liebman HA , Carfagno MK , Weitz IC , et al. Excessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinase. Am J Clin Pathol 1992;98:534.

23.

Gastineau DA , Gertz MA , Daniels TM , Kyle RA , Bowie EJ Inhibitor of the thrombin time in systemic amyloidosis: a common coagulation abnormality. Blood 1991;15:2637.

24.

Hoshino Y. , Hatake K. , Muroi K. , et al. Bleeding tendency caused by the deposit of amyloid substance in the perivascular region. Intern Med 1993 ;32:879.

25.

Tomura S. , Nakamura Y. , Tachibana K. , et al. Enhanced coagulation and fibrinolysis during treatment with recombinant human erythropoietin in patients undergoing chronic hemodialysis . Blood Purif 1993;11:370.

26.

Takahashi H. , Koike T. , Yoshid N. , et al. Excessive fibrinolysis in suspected amyloidosis: demonstrations of plasmin-α2 plasmin inhibitor complex and von Willebrand factor fragment in plasma. Am J Hematol 1986;23:153.